H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer

The study was performed to identify the role of H3K9 methylation in prostate cancer. This experiment was conducted to determine the genomic localization of H3K9me2 and H3K9me3 in naïve, short-term antiandrogen treated and antiandrogen resistant prostate cancer cells. Overall design: Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for histone modifications H3K9me2 and H3K9me3 in naïve LNCaP, short-term antiandrogen treated LNCaP and LNCaP EnzR cells.